Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.48 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6214461 | 0.96 | KAT2B (0.73) | KAT2BMAPTLMNAPKMRAB9A | |
| SCHEMBL6220073 | 0.95 | KAT2B (0.71) | KAT2BMAPTLMNAPKMRAB9A | |
| SCHEMBL112161 | 0.92 | KAT2B (0.70) | KAT2BMAPTLMNAPKMRAB9A | |
| SCHEMBL29519350 | 0.92 | KAT2B (0.70) | KAT2BMAPTLMNAPKMRAB9A | |
| SCHEMBL29519405 | 0.86 | KAT2B (0.73) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL6216875 | 0.85 | KAT2B (0.77) | KAT2BMAPTLMNAPKMPRSS1 | |
| Hydrochloric Acid SCHEMBL514469 | 0.85 | KAT2B (1.00) | KAT2BMAPTLMNAPKMPRSS1 | |
| SCHEMBL8246358 | 0.85 | KAT2B (0.58) | KAT2BMAPTLMNAPKMRAB9A | |
| SCHEMBL9516451 | 0.85 | KAT2B (0.61) | KAT2BMAPTLMNAPKMRAB9A | |
| SCHEMBL27655316 | 0.84 | KAT2B (0.71) | KAT2BMAPTLMNAPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113544121-A | Heterocyclic derivative with beta 2 receptor agonistic and M receptor antagonistic activities and medical application thereof | 中国医药研究开发中心有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-107074833-B | Having beta2Benzo ring derivatives with receptor agonistic and M3 receptor antagonistic activities and application thereof in medicine | 四川海思科制药有限公司 | 2021-05-25 | — | — | CN | disclosed |
| WO-2020244452-A1 | HETEROCYCLIC DERIVATIVE HAVING β2 RECEPTOR AGITATION AND M RECEPTOR ANTAGONISTIC ACTIVITY AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2020-12-10 | — | — | WO | disclosed |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-10300072-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2019-05-28 | — | — | US | disclosed |
| EP-3375781-A1 | BENZO RING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-20180015097-A1 | CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2018-01-18 | — | — | US | disclosed |
| US-9757383-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-09-12 | — | — | US | disclosed |
| CN-107074833-A | With β2The Benzocyclodirivative of receptor agonism and M3 receptor antagonist activities and its in purposes pharmaceutically | 四川海思科制药有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-2592077-A1 | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities | Almirall, S.A. (ES) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592078-A1 | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities | Almirall, S.A. (ES) | 2013-05-15 | — | — | EP | disclosed |
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1461035-A4 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1461035-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003053344-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| EP-1196391-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005770-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300072-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ADRB2, CHRM3, CHRM2 | KAT2B 3876/4885MAPT 2951/4885LMNA 1885/4885 |
| US-20190185461-A1 | BENZOCYCLIC DERIVATIVE HAVING B2-RECEPTOR AGONIST ACTIVITY AND M3-RECEPTOR ANTAGONIST ACTIVITY AND MEDICAL USE THEREOF | HCAR2, CHRM3, BDKRB2 | KAT2B 2131/4885MAPT 3209/4885LMNA 2286/4885 |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | KAT2B 3405/4885MAPT 4825/4885LMNA 2721/4885 |
| US-20180015097-A1 | CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | KAT2B 3711/4885MAPT 2957/4885LMNA 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.